Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
The closest pipeline candidates are orforglipron, the first non-peptide oral GLP-1 from Eli Lilly, with an FDA decision anticipated in 2026, and retatrutide, a triple GLP-1/GIP/glucagon agonist in phase 3
With an organic blend of Vitamin B3, Vitamin C, and other essential nutrients, show off the best version of your skin, regardless of type
STOPP/START criteria for potentially inappropriate prescribing in older people: version 2
The most common (water retention, tingling, injection site reactions) resolve on their own or with dose adjustments
List downloaded from Dataset DOI:10.5281/zenodo.4587355 C07AB03 S66 | EAWAGTPS | Parent-Transformation Product Pairs from Eawag | DOI:10.5281/zenodo.3754448 C07AB03 S66 | EAWAGTPS | Parent-Transformation Product Pairs from Eawag | DOI:10.5281/zenodo.3754448 C - Cardiovascular system C07 - Beta blocking agents C07A - Beta blocking agents C07AB - Beta blocking agents, selective C07AB03 - Atenolol Absorption Approximately 50% of an oral dose is absorbed from the gastrointestinal tract, with the remainder being excreted unchanged in the feces
No need to leave home, delivery in just 1 hour
US$ 24.02
US$ 21.37
US$ 28.59
US$ 28.59
US$ 28.81
US$ 25.69
US$ 29.61
US$ 25.43
